Innovent Biopharmaceutical Transformation

Keep Advancing Robust Pipeline Assets in 2022 Early Stage +8 Рос +5 Pivotal NDA Approved +4 +4 +2 Additional 8-10 novel molecules to enter first-in- human study in China and ex-China PDL1/4-1BB CD73 Additional 5 Molecules to receive PoC or preliminary PoC data and possibly move to further studies VEGF/C LAG-3 SIRPa PD-L1/CD47 CLDN18.2 mAb PD-1/IL-2 PD-L1/LAG-3 TIGIT At least additional 4 molecules are planned to enter pivotal or registrational studies this year ROS1 CD47 KRAS G12C GLP-1/GCGR IL-23 Additional 3 to 4 late stage pipeline to file NDA BCMA CAR-T CTLA-4 PCSK-9 РІЗКО* Anticipate two more products to receive regulatory approval PD-1 VEGF TNFα CD20 FGFR1/2/3 BCR/ABL PD-1/IL-21/IL-2 VEGF/ANG-2 VEGF-A/VEGF-C CLDN18.2 ADC CLDN18.2 CAR-T CLDN18.2/CD3 IGF-1R PDE4 PD-1/TIGIT Innovent VEGFR-2 RET CYRAMZA™ ramucirumab injection 10 mg/ml solution Retevmo Anticipated Pipeline Progress in Year 2022 Confidential Copyright©2022 Innovent *Note: We plan to have communication with China NMPA regarding the potential submission of PI3KS. Incyte has withdrawn the application of parsaclisib in FL, MZL and MCL in the U.S. as a business decision and is not related to any changes in either the efficacy or safety of parsaclisib. 18

View entire presentation